NanosonicsASX:NAN -1.83%83 FCF Margin % is 4.25% as of Dec. 2025, which is 61% below its 10-year median of 11.00. GuruFocus rates ASX:NAN with a GF Score™ of 83/100 and a GF Value™ of A$4.49 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 815 Medical Devices & Instruments companies, Nanosonics ranks better than 77.42% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nanosonics's Free Cash Flow for the
six
months ended in Dec. 2025 was A$4.3 Mil. Nanosonics's Revenue for the
six
months ended in Dec. 2025 was A$102.2 Mil. Therefore, Nanosonics's FCF Margin % for the quarter that ended in Dec. 2025 was 4.25%.
The historical rank and industry rank for Nanosonics's FCF Margin % or its related term are showing as below:
ASX:NAN'
s FCF Margin % Range Over the Past 10 Years
Min: -0.23 Med: 11 Max: 22.4
Current: 11.75
During the past 13 years, the highest FCF Margin % of Nanosonics was 22.40%. The lowest was -0.23%. And the median was 11.00%.
ASX:NAN's FCF Margin % is ranked better than 77.42% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.03
vs ASX:NAN: 11.75
Nanosonics FCF Margin % Related Terms
Nanosonics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Nanosonics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:NAN vs ISRG, BDX, MDLN: FCF Margin % Comparison
For the Medical Instruments & Supplies subindustry, Nanosonics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosonics FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Nanosonics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanosonics (ASX:NAN) has a FCF Margin % of 4.25% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nanosonics and its competitors. This is 61% below median its historical median of 11.00. According to the industry distribution chart, Nanosonics ranks #184 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 22.6%.
Is Nanosonics' FCF Margin % too high?
Nanosonics' current FCF Margin % of 4.25% is 61% below median its 10-year median of 11.00. Based on the distribution chart, Nanosonics ranks #184 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nanosonics has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanosonics' FCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nanosonics ranks #184 out of 815 companies for FCF Margin %. This places Nanosonics in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nanosonics and its competitors. Nanosonics's current FCF Margin % is 4.25%, which is 61% below median its own 10-year median of 11.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosonics stock overvalued right now?
Based on GuruFocus' analysis, Nanosonics (ASX:NAN) is currently considered Modestly Undervalued. The stock's GF Value™ is A$4.49, compared to a current price of A$3.22 — trading 28.3% below its estimated fair value. The current FCF Margin % is 4.25%, which is 61% below median its 10-year median of 11.00. Nanosonics' overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Nanosonics (ASX:NAN), the current FCF Margin % is 4.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanosonics (ASX:NAN) Overvalued in 2026?
Based on GuruFocus' analysis, Nanosonics stock appears to be undervalued.
The current stock price of A$3.22 is trading 28.3% below its estimated GF Value™ of A$4.49.
GuruFocus considers Nanosonics to be Modestly Undervalued.
Key valuation signals for ASX:NAN:
FCF Margin %: 4.25% (61% below median its 10-year median of 11.00)
GF Value™: A$4.49 vs. price of A$3.22 (28.3% below fair value)
No single metric tells the full story. See the ASX:NAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanosonics is largely a single-product firm, and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics' revenue consists of capital sales of Trophon units, ongoing consumables sales, and service revenue. By December 2025, there were 38,000 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, over 50% in the US to single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
83GF Score
Get the complete analysis for ASX:NAN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NAN has been successfully added to your 
